Comparative pharmacokinetics and pharmacodynamics of platelet adenosine diphosphate receptor antagonists and their clinical implications.
about
Applications of CYP450 testing in the clinical settingIndividualization of treatments with drugs metabolized by CES1: combining genetics and metabolomics.Drug-Free Platelets Can Act as Seeds for Aggregate Formation During Antiplatelet Therapy.Synthesis and Anti-Platelet Activity of Thiosulfonate Derivatives Containing a Quinone Moiety.Synergistic Inhibition of Both P2Y1 and P2Y12 Adenosine Diphosphate Receptors As Novel Approach to Rapidly Attenuate Platelet-Mediated Thrombosis.Gradual increase in thrombogenicity of juvenile platelets formed upon offset of prasugrel medication.Pharmacogenetics and cardiovascular disease--implications for personalized medicinePharmacokinetic considerations for antithrombotic therapies in stroke.Pharmacology of the new P2Y12 receptor inhibitors: insights on pharmacokinetic and pharmacodynamic properties.Clinical implications of drug-drug interactions with P2Y12 receptor inhibitors.Oral antiplatelet therapy: impact for transfusion medicine.Disaggregation Following Agonist-Induced Platelet Activation in Patients on Dual Antiplatelet Therapy.In-hospital switching between adenosine diphosphate receptor inhibitors in patients with acute myocardial infarction treated with percutaneous coronary intervention: Insights into contemporary practice from the TRANSLATE-ACS study.Grapefruit juice and clopidogrel.Circadian variation of stent thrombosis and the effect of more robust platelet inhibition: a post hoc analysis of the TRITON-TIMI 38 trial.Reversal strategy in antagonizing the P2Y12 -inhibitor ticagrelor.Higher body weight patients on clopidogrel maintenance therapy have lower active metabolite concentrations, lower levels of platelet inhibition, and higher rates of poor responders than low body weight patients.Impact of ticagrelor on P2Y1 and P2Y12 localization and on cholesterol levels in platelet plasma membrane.Genetic Understanding of Stroke Treatment: Potential Role for Phosphodiesterase Inhibitors.Ticagrelor inhibits platelet-tumor cell interactions and metastasis in human and murine breast cancer.A retrospective comparison between delayed and early hip fracture surgery in patients taking clopidogrel: same total bleeding but different timing of blood transfusion.Clopidogrel bioactivation and risk of bleeding in patients cotreated with angiotensin-converting enzyme inhibitors after myocardial infarction: a proof-of-concept study.Novel aspects of antiplatelet therapy in cardiovascular disease
P2860
Q24621760-D2D88935-BFD6-4E72-9BA6-63271C0030B3Q30373969-B1658BF3-7955-4A6B-9FC3-A89784470031Q36104404-1D1C02DB-2511-44AA-BDA3-BCFF888B0B58Q36505025-28C8F760-F08E-4D48-8B0A-9F949EE0E7B8Q36619562-7CB8DD87-6595-4D63-9030-E6C27D19FDEAQ36709028-D5BCF24E-9762-499A-8B19-562A98D5C5DDQ36974672-DA31BEBF-80FC-4359-8077-5F00507BE62DQ38113231-4A574605-E3D8-4270-94D1-97A1CED99D80Q38151563-822C7F26-AFE5-44DE-ABBA-40996D5D4A20Q38177048-4C89DC46-DE4A-45E4-908C-A7E687843433Q38754884-6C1EF4A3-EB35-4FD4-BCE6-A512F5C95C7FQ41620557-C7215AC3-1336-4F19-AF4B-B09D6788B39DQ41681914-477D7CC5-70C5-457F-97AE-404AD1CCAC37Q42582391-254681A4-A93C-4061-9E2F-FA4B2E376408Q44101182-8F0A4AA9-3BE5-4AF2-B7FA-D9254A174146Q45276265-51FFB3B0-EDE8-4F4A-BF8F-9079E1563D21Q47210349-8549EE69-0BA9-492B-8EC4-4B4557B28880Q47666744-4971E9B6-E326-4E7B-B451-CE52B9940577Q48093627-BDB574D1-94CF-4606-ADB8-712EECAD7B1FQ48265369-B4D1DBD1-FA9C-4080-8231-CF27D9E5D5B2Q48345376-03A369AC-7EA9-46B9-BCF5-D922C6A583FBQ50622756-C0DA5E5E-0E6C-43AE-9070-05562AD728A7Q57179203-42349B86-4F3C-47F8-BC10-2DEE88ED89E6
P2860
Comparative pharmacokinetics and pharmacodynamics of platelet adenosine diphosphate receptor antagonists and their clinical implications.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Comparative pharmacokinetics a ...... d their clinical implications.
@en
type
label
Comparative pharmacokinetics a ...... d their clinical implications.
@en
prefLabel
Comparative pharmacokinetics a ...... d their clinical implications.
@en
P2860
P1476
Comparative pharmacokinetics a ...... d their clinical implications.
@en
P2093
Christopher N Floyd
Gabriella Passacquale
P2860
P304
P356
10.2165/11630740-000000000-00000
P50
P577
2012-07-01T00:00:00Z
P5875
P6179
1028400979